Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Reference-Cited by-同舟云学术

Profile of Immunoglobulin G and IgM Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Published:2020-04-27 Issue:16 Volume:71 Page:2255-2258
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Qu Jiuxin¹,Wu Chi¹,Li Xiaoyong¹,Zhang Guobin¹,Jiang Zhaofang¹,Li Xiaohe²,Zhu Qing¹,Liu Lei³

Affiliation:

1. Department of Clinical Laboratory, The Third People’s Hospital of Shenzhen, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China

2. Department of Infectious Diseases, The Third People’s Hospital of Shenzhen, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China

3. The Third People’s Hospital of Shenzhen, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China

Abstract

Abstract We profiled the serological responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (N) protein and spike (S) glycoprotein. The majority of the patients developed robust antibody responses between 17 and 23 days after illness onset. Delayed, but stronger, antibody responses were observed in critical patients.

Funder

Shenzhen Key Laboratory of Biochip

Bill and Melinda Gates Foundation

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa489/33346758/ciaa489.pdf

Reference10 articles.

1. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China;Huang;The Lancet,2020

2. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study;Yang;Lancet Respir Med,2020